Search

Search Constraints

You searched for: Author/Creator Schnaidt, Sven

Search Results

1. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial. (8th February 2021)

3. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Issue 4 (26th January 2021)

4. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Issue 4 (26th January 2021)

5. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Issue 16 (19th October 2021)

6. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Issue 16 (29th August 2021)

7. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. Issue 9 (28th June 2022)

8. Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population‐based GENICA study and external genetic databases. Issue 2 (25th February 2013)

9. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Issue 3 (15th January 2019)

10. Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes. (November 2019)